Publication: CEACAM1 as a multi-purpose target for cancer immunotherapy
Loading...
Open/View Files
Date
2017
Published Version
Journal Title
Journal ISSN
Volume Title
Publisher
Taylor & Francis
The Harvard community has made this article openly available. Please share how this access benefits you.
Citation
Dankner, Matthew, Scott D. Gray-Owen, Yu-Hwa Huang, Richard S. Blumberg, and Nicole Beauchemin. 2017. “CEACAM1 as a multi-purpose target for cancer immunotherapy.” Oncoimmunology 6 (7): e1328336. doi:10.1080/2162402X.2017.1328336. http://dx.doi.org/10.1080/2162402X.2017.1328336.
Abstract
ABSTRACT CEACAM1 is an extensively studied cell surface molecule with established functions in multiple cancer types, as well as in various compartments of the immune system. Due to its multi-faceted role as a recently appreciated immune checkpoint inhibitor and tumor marker, CEACAM1 is an attractive target for cancer immunotherapy. Herein, we highlight CEACAM1's function in various immune compartments and cancer types, including in the context of metastatic disease. This review outlines CEACAM1's role as a therapeutic target for cancer treatment in light of these properties.
Description
Other Available Sources
Research Data
Keywords
Cancer, cancer immunotherapy, cancer therapy, CEACAM1, NK cells, T cells, tumor marker
Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service